Skip to content

Comparing Speedlyte and IV Rehydration Treating Children With Gastroenteritis in a Pediatric Emergency Department (ED)

Comparative Study Between the Oral Rehydration Product, Speedlyte, With Lipophilic Absorption and IV Rehydration in Treatment of Children With Gastroenteritis in a Pediatric Emergency Department

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03562702
Enrollment
5
Registered
2018-06-19
Start date
2018-07-01
Completion date
2020-01-22
Last updated
2020-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Gastroenteritis, Dehydration

Keywords

vomiting, diarrhea

Brief summary

To compare length of stay (LOS) of pediatric patients in a pediatric emergency room presenting with Gastroenteritis treated with IV rehydration versus oral Speedlyte rehydration.

Detailed description

Gastroenteritis leading to dehydration is very commonly encountered in the pediatric emergency room setting. Oral rehydration therapy (ORT) is the first line therapy recommended by the American Academy of Pediatrics but is seldom used compared to intravenous therapy (IVT). ORT has many advantages including less traumatic to the patient, can be administered by mouth, can be administered at home and less costly compared to IVT. Furthermore, intravenous fluids may present several complications with IV placement such as infiltration, hematoma, air embolism, phlebitis, extravascular injection, intraarterial injection, etc. Speedlyte is a new oral rehydration product with lipophilic absorption which allows for electrolytes to be more readily absorbed compared to other oral rehydration solutions. The liposome encapsulates the salty molecules which is thought to decrease the negative salty taste associated with oral rehydration solutions. In addition, the encapsulation of electrolytes allows for more molecules to be delivered past the stomach acids and absorbed into the body under higher bioavailability due to the lipid shell. Participants will be randomized into two rehydration groups. One group will receive oral rehydration with the Speedlyte product, the amount will be based on the participant's weight. The other group will receive intravenous rehydration with a normal saline bolus per physician practice, usually in the amount of 20 mL/kg. These interventions can be incorporated into the emergency room practice without undue expense to the setting or placing excessive demands on nursing time as these practices are standard of care in many rehydration cases.

Interventions

OTHERStandard IV Rehydration Therapy

IV rehydration group receiving a Normal Saline bolus of IVF (usually 20 ml/kg)

Speedlyte oral solution as rehydration therapy based on participant's weight (10 m/l kg over one hour). Total of 150 ml/kg over 24 hours prior to discharge

Sponsors

Einsoff Biohealth
CollaboratorOTHER
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Masking description

The assignment of treatment will be concealed from research team members involved in recruiting patients by using sealed, sequentially numbered, opaque envelopes containing the type of rehydration treatment to be used.

Eligibility

Sex/Gender
ALL
Age
6 Months to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* 6 mths to 18 years; * Signs and symptoms of dehydration for less than a week * Diagnosis of acute gastroenteritis, dehydration, vomiting, and/or diarrhea; * Patient able to drink from bottle and/or cup; * Per clinician's judgment, patient needs rehydration with IV solution.

Exclusion criteria

* Chronic disease that includes but not limited to TB, HIV, congenital heart disease with hemodynamic consequences, metabolic disease, cerebral palsy, adrenal hyperplasia, renal tubular acidosis, and nephropathy; * Vomiting due to head trauma; * Severe hydration; * Diabetic ketoacidosis; * Bloody diarrhea; * Diarrhea for more than a week; * Malnutrition; * Burns; * Pneumonia; * Meningitis; * History of seizures; * Absent bowel sounds; * Not able to drink from bottle or cup; * Previous allergic reaction to citrate or other food coloring particles/formulation; * Parent/legal guardian refusing to participate.

Design outcomes

Primary

MeasureTime frameDescription
Length of stay (LOS)up to 24 hoursComparison of length of stay (LOS) in a pediatric emergency department in the treatment of acute gastroenteritis between the oral rehydration solution Speedlyte and intravenous rehydration.

Secondary

MeasureTime frameDescription
Adjunct Medicationup to 24 hoursNumber of adjunct medications given in the ED in both groups

Other

MeasureTime frameDescription
Time to initiation of therapyup to 24 hoursTime to initiation of therapy in each group
Number of patients that fail to rehydrateup to 24 hoursObtain the number of patients that fail to rehydrate in each group. Oral requiring IV intervention, IV requiring further fluids and/or admission.
Hospitalization rateup to 24 hoursThe rate of hospitalization for each group
Revisit rate in each group.up to 24 hoursThe revisit rate for each group

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026